Abstract 50: Shape of the TPA Time - Benefit Curve: Insights From The National US Get With The Guidelines - Stroke Population
Background: Randomized trials demonstrated benefit of IV tissue plasminogen activator (tPA) is strongly time-dependent, but were underpowered to specify the shape of the time - benefit curve. Large registries can provide insight into how quickly benefits of tPA decay with time.
Methods: We analyzed the relationship between onset to treatment (OTT) and 4 outcomes, discharge to home, discharge free of disability (mRS 0-1), discharge ambulatory status, and mortality, in acute ischemic stroke patients treated with tPA within 4.5h in 1456 GWTG-Stroke hospitals from Jan 2009 to Sept 2013.
Results: Among the 65,384 tPA-treated patients, median age was 72, 50.5% were female, median OTT was 141 mins (IQR 110-173), and 11.3% (7368) had OTT 0-90m, 71.1% (46,457) had OTT 91-180m, and 17.6% (11,559) had OTT 181-270m. A slight curvilinear relationship was observed between OTT and discharge to home and discharge free of disability, with inflection at 150 minutes (Figure). Discharge free of disability showed rapid decline between 15-150m (11 fewer patients per 1000 treated per 15m delay) and slower decline from 151-270m (5 fewer per 1000 treated per 15m delay). In contrast, a linear relationship with OTT throughout the 15-270 minute window was observed for independent ambulation at discharge (8 fewer per 1000 treated per 15m delay) and in-hospital mortality (2 fewer per 1000 treated per 15m delay). Considering all mRS disability scale transitions, benefit declined more rapidly in the first and second hours (25 and 33 worse outcomes per 1000 treated per 15m delay) compared to 3-4.5 hours (11 worse outcomes per 1000 treated per 15m delay).
Conclusions: Rates of excellent, disability-free outcome and of discharge to home after IV tPA decay more rapidly in the first 2.5 hours after stroke onset, while independent ambulation and mortality decline in a linear fashion throughout the 4.5 hour window. Speedier start of tPA treatment within the first 2.5 hours after onset maximizes treatment benefit.
Author Disclosures: J.L. Saver: Other; Modest; Dr. Saver is an employee of the University of California. The University of California, Regents receive funding for Dr Saver’s services as a scientific consultant regarding trial design and conduct to. G.C. Fonarow: Other; Modest; Dr, Fonarow is an employee of the University of California, which has patent rights in retrieval devices for stroke.. E.E. Smith: None. M.J. Reeves: None. D. Navalkele: None. J.C. Grotta: Research Grant; Modest; Genetech, Lundbeck, Haemonetics, Covidien, Zoll. Consultant/Advisory Board; Modest; Specialists on Call, Frazer, Stryker. M.V. Grau-Sepulveda: None. A.F. Hernandez: Research Grant; Modest; Johnson & Johnson. Consultant/Advisory Board; Modest; AstrazZeneca, Amgen. E.D. Peterson: Research Grant; Modest; Johnson & Johnson, Lilly, Bristol Myers Squibb, Sanofi-Aventis, Merck-Schering Plough. L. Schwamm: Other Research Support; Modest; Genentech. Consultant/Advisory Board; Modest; Lundbeck, Penumbra.
This research has received full or partial funding support from the American Heart Association, National Center.
- © 2015 by American Heart Association, Inc.